These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 28418652)

  • 1. Design and Development of Highly Potent HIV-1 Protease Inhibitors with a Crown-Like Oxotricyclic Core as the P2-Ligand To Combat Multidrug-Resistant HIV Variants.
    Ghosh AK; Rao KV; Nyalapatla PR; Osswald HL; Martyr CD; Aoki M; Hayashi H; Agniswamy J; Wang YF; Bulut H; Das D; Weber IT; Mitsuya H
    J Med Chem; 2017 May; 60(10):4267-4278. PubMed ID: 28418652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and Synthesis of Highly Potent HIV-1 Protease Inhibitors Containing Tricyclic Fused Ring Systems as Novel P2 Ligands: Structure-Activity Studies, Biological and X-ray Structural Analysis.
    Ghosh AK; R Nyalapatla P; Kovela S; Rao KV; Brindisi M; Osswald HL; Amano M; Aoki M; Agniswamy J; Wang YF; Weber IT; Mitsuya H
    J Med Chem; 2018 May; 61(10):4561-4577. PubMed ID: 29763303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-Based Design of Highly Potent HIV-1 Protease Inhibitors Containing New Tricyclic Ring P2-Ligands: Design, Synthesis, Biological, and X-ray Structural Studies.
    Ghosh AK; Kovela S; Osswald HL; Amano M; Aoki M; Agniswamy J; Wang YF; Weber IT; Mitsuya H
    J Med Chem; 2020 May; 63(9):4867-4879. PubMed ID: 32348139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance.
    Ghosh AK; Chapsal BD; Weber IT; Mitsuya H
    Acc Chem Res; 2008 Jan; 41(1):78-86. PubMed ID: 17722874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design of Highly Potent, Dual-Acting and Central-Nervous-System-Penetrating HIV-1 Protease Inhibitors with Excellent Potency against Multidrug-Resistant HIV-1 Variants.
    Ghosh AK; Rao KV; Nyalapatla PR; Kovela S; Brindisi M; Osswald HL; Sekhara Reddy B; Agniswamy J; Wang YF; Aoki M; Hattori SI; Weber IT; Mitsuya H
    ChemMedChem; 2018 Apr; 13(8):803-815. PubMed ID: 29437300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Piperidine scaffold as the novel P2-ligands in cyclopropyl-containing HIV-1 protease inhibitors: Structure-based design, synthesis, biological evaluation and docking study.
    Zhou H; Zhu M; Ma L; Zhou J; Dong B; Zhang G; Cen S; Wang Y; Wang J
    PLoS One; 2020; 15(7):e0235483. PubMed ID: 32697773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural Analysis of Potent Hybrid HIV-1 Protease Inhibitors Containing Bis-tetrahydrofuran in a Pseudosymmetric Dipeptide Isostere.
    Rusere LN; Lockbaum GJ; Henes M; Lee SK; Spielvogel E; Rao DN; Kosovrasti K; Nalivaika EA; Swanstrom R; Kurt Yilmaz N; Schiffer CA; Ali A
    J Med Chem; 2020 Aug; 63(15):8296-8313. PubMed ID: 32672965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, Synthesis and X-Ray Structural Studies of Potent HIV-1 Protease Inhibitors Containing C-4 Substituted Tricyclic Hexahydro-Furofuran Derivatives as P2 Ligands.
    Ghosh AK; Kovela S; Sharma A; Shahabi D; Ghosh AK; Hopkins DR; Yadav M; Johnson ME; Agniswamy J; Wang YF; Hattori SI; Higashi-Kuwata N; Aoki M; Amano M; Weber IT; Mitsuya H
    ChemMedChem; 2022 May; 17(9):e202200058. PubMed ID: 35170223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Substituted Bis-THF Protease Inhibitors with Improved Potency against Highly Resistant Mature HIV-1 Protease PR20.
    Agniswamy J; Louis JM; Shen CH; Yashchuk S; Ghosh AK; Weber IT
    J Med Chem; 2015 Jun; 58(12):5088-95. PubMed ID: 26010498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-based design of potent HIV-1 protease inhibitors with modified P1-biphenyl ligands: synthesis, biological evaluation, and enzyme-inhibitor X-ray structural studies.
    Ghosh AK; Yu X; Osswald HL; Agniswamy J; Wang YF; Amano M; Weber IT; Mitsuya H
    J Med Chem; 2015 Jul; 58(13):5334-43. PubMed ID: 26107245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design of HIV-1 Protease Inhibitors with Amino-bis-tetrahydrofuran Derivatives as P2-Ligands to Enhance Backbone-Binding Interactions: Synthesis, Biological Evaluation, and Protein-Ligand X-ray Studies.
    Ghosh AK; Martyr CD; Osswald HL; Sheri VR; Kassekert LA; Chen S; Agniswamy J; Wang YF; Hayashi H; Aoki M; Weber IT; Mitsuya H
    J Med Chem; 2015 Sep; 58(17):6994-7006. PubMed ID: 26306007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance.
    Ghosh AK; Sridhar PR; Leshchenko S; Hussain AK; Li J; Kovalevsky AY; Walters DE; Wedekind JE; Grum-Tokars V; Das D; Koh Y; Maeda K; Gatanaga H; Weber IT; Mitsuya H
    J Med Chem; 2006 Aug; 49(17):5252-61. PubMed ID: 16913714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent HIV-1 protease inhibitors incorporating meso-bicyclic urethanes as P2-ligands: structure-based design, synthesis, biological evaluation and protein-ligand X-ray studies.
    Ghosh AK; Gemma S; Takayama J; Baldridge A; Leshchenko-Yashchuk S; Miller HB; Wang YF; Kovalevsky AY; Koh Y; Weber IT; Mitsuya H
    Org Biomol Chem; 2008 Oct; 6(20):3703-13. PubMed ID: 18843400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro.
    Amano M; Koh Y; Das D; Li J; Leschenko S; Wang YF; Boross PI; Weber IT; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2007 Jun; 51(6):2143-55. PubMed ID: 17371811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, Synthesis, Biological Evaluation, and X-ray Studies of HIV-1 Protease Inhibitors with Modified P2' Ligands of Darunavir.
    Ghosh AK; Fyvie WS; Brindisi M; Steffey M; Agniswamy J; Wang YF; Aoki M; Amano M; Weber IT; Mitsuya H
    ChemMedChem; 2017 Dec; 12(23):1942-1952. PubMed ID: 29110408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design of gem-difluoro-bis-tetrahydrofuran as P2 ligand for HIV-1 protease inhibitors to improve brain penetration: synthesis, X-ray studies, and biological evaluation.
    Ghosh AK; Yashchuk S; Mizuno A; Chakraborty N; Agniswamy J; Wang YF; Aoki M; Gomez PM; Amano M; Weber IT; Mitsuya H
    ChemMedChem; 2015 Jan; 10(1):107-15. PubMed ID: 25336073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Probing multidrug-resistance and protein-ligand interactions with oxatricyclic designed ligands in HIV-1 protease inhibitors.
    Ghosh AK; Xu CX; Rao KV; Baldridge A; Agniswamy J; Wang YF; Weber IT; Aoki M; Miguel SG; Amano M; Mitsuya H
    ChemMedChem; 2010 Nov; 5(11):1850-4. PubMed ID: 20827746
    [No Abstract]   [Full Text] [Related]  

  • 18. A Photochemical Route to Optically Active Hexahydro-4
    Ghosh AK; Robinson WL
    J Org Chem; 2019 Aug; 84(15):9801-9805. PubMed ID: 31310117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Protease Inhibitors Containing C-5-Modified
    Takamatsu Y; Aoki M; Bulut H; Das D; Amano M; Sheri VR; Kovari LC; Hayashi H; Delino NS; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31085520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir.
    Lefebvre E; Schiffer CA
    AIDS Rev; 2008; 10(3):131-42. PubMed ID: 18820715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.